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ABSTRACT Drug treatment poses a therapeutic 
challenge in cystic fibrosis (CF) because the 
disposition of a number of drugs is altered in CF. 
Enhanced clearance of acetaminophen (APAP) and 
indocyanine green (ICG) have previously been 
reported in CF patients. The objective of the current 
study was to investigate if the CF-knockout mouse 
model (cftr
m1UNC
) shows altered pharmacokinetics 
similar to those seen in CF patients using the 2 model 
compounds APAP and ICG. Clearance (CL/F) of 
APAP and renal (CLR) and formation (CLf) clearance 
of acetaminophen glucuronide (AG) and 
acetaminophen sulfate (AS) were determined in CF-
knockout mice following administration of APAP (50 
mg/kg, intraperitoneal). CLR of AS was 19.5 and 12.9 
(mL/min per kg) and CLf of AS was 10.4 and 6.7 
mL/min per kg for homozygous and heterozygous 
males, respectively, which was significantly different 
between groups. CLR of AG was 6.3 and 4.8 mL/min 
per kg and CLf of AG was 9.6 and 8.9 mL/min per kg 
for homozygous and heterozygous males, 
respectively, although not reaching statistical 
significance. No significant differences were noted in 
either ClR or CLf of AG and AS in female CF mice. 
Plasma concentrations of ICG (10 mg/kg, 
intravenous) were determined over 0 to 15 minutes. 
Homozygous females showed a higher apparent 
volume of distribution (96 mL/kg) relative to 
heterozygous females (72 mL/kg). Similar to CF 
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patients, a trend toward a lower Cmax was noted in 
homozygous male and female mice. However, 
contrary to human data, no significant differences in 
CL of ICG were noted. These results suggest that the 
CF-knockout mice have potential as a model for 
studying altered drug disposition in CF patients. 
INTRODUCTION
Cystic fibrosis (CF) is the most common fatal genetic 
disease in the Western world. In the United States, 
approximately 30,000 people are living with the 
disease, and there are 1,000 new cases diagnosed 
each year. About 5% of Caucasians are asymptomatic 
carriers, and 1 child in approximately 2,500 of 
European descent carries 2 defective copies of the 
gene and has the disease (1). In general, altered 
pharmacokinetics of numerous drugs in the CF 
population include increased volume of distribution 
(Vd), decreased plasma concentrations, and enhanced 
renal and non-renal clearance of drugs. 
The mechanistic basis for the altered 
pharmacokinetics in CF is unknown, although 
alterations in hepatic metabolism, blood flow, or 
transport have been suggested (2-4). Determining a 
mechanism for altered pharmacokinetics of drugs in 
CF is unlikely if experimentation is limited to clinical 
studies. The use of an appropriate animal model to 
study this phenomenon is highly desirable because it 
would permit more invasive investigations and 
provide the ability to perform biochemical studies 
with isolated tissues. 
In the present study, we test the hypothesis that the 
CF-knockout mouse can be used as an animal model 
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to predict the altered pharmacokinetics of drugs in 
CF. Increased clearance of acetaminophen (APAP) 
and indocyanine green (ICG) has been reported in CF 
patients (2-5). In order to test the above hypothesis, 
pharmacokinetics of 2 model compounds, APAP and 
ICG, were studied in CF-mice. Results from the 
study indicate that CF-knockout mice appear 






-knockout mice generated at the University 
of North Carolina-Chapel Hill animal facility were 
used in this study and are a hybrid strain containing 
genetic material from C57BL/6, 129/SvEv, Balb/c, 
and DBA/2 mice (6). Cftr
m1UNC
-knockout mice breed 
and pass on the defective cftr gene in a simple 
Mendelian pattern (7). Cftr
m1UNC
-knockout mice are 
maintained on Colyte (PEG 3350 and electrolytes) to 
prevent intestinal obstructions, resulting in soft stools 
without diarrhea (6).  
Genotyping the cftrmiUNC-knockout mice  
Tail DNA from the CF-mice was isolated and stored 
at 2 to 8°C in Tris-EDTA using the protocol of Miller 
et al, 1988 (8). Mice were then genotyped by 
polymerase chain reaction (PCR) (Robocycler; 
Stratagene, La Jolla, CA) using a protocol provided 
by the Cystic Fibrosis Center, University of North 
Carolina-Chapel Hill. Primers used were 67 Common 
primer (CAG TGA AGC TGA GAC TGT GAG 
CTT), 3215+ (CTG TAG TTG GCA AGC TTT 
GAC), and 45- (ACA CTG CTC GAG GGC TAG 
CCT CTT C). Products of the PCR were run on a 1% 
agarose gel, followed by staining with ethidium 
bromide, and were viewed on an ultraviolet 
transilluminator. 
Materials 
APAP, acetaminophen glucuronide (AG), 3-
acetamidophenol, and ICG were purchased from 
Sigma Chemical (St. Louis, MO). Acetaminophen 
sulfate (AS) was generously provided by Dr. Marilyn 
Morris (State University of New York at Buffalo, 
Buffalo, NY). 
Animal Treatment 
For studies with APAP, adult mice (cftr
m1UNC
) were 
housed individually in metabolism cages with free 
access to food and water. Each mouse was 
administered 50 mg/kg of APAP as a 10 mg/mL 
solution. Urine was collected over 18 hours, then 
centrifuged to remove solid contaminants. The 
volume of the supernatant was measured then frozen 
at -20
o
C. After a washout period of 7 days, the same 
mice were injected with APAP (50 mg/kg, 
intraperitoneal [ip]), and blood samples were 
collected sequentially by tail artery bleeding at 0, 15, 
30, 45, 60, 120, and 180 minutes in males and 0, 5, 
10, 15, 20, 25, 30, 45, 60, 120, and 180 minutes in 
females. The samples were then centrifuged, and 
plasma was frozen at -20
o
C until high-performance 
liquid chromatography (HPLC) analysis. For studies 
with ICG, mice were injected with ICG (10 mg/kg, 
intravenous [iv]) via the tail vein as a 2 mg/mL 
solution. The solution was made daily and protected 
from light to minimize degradation. Blood was 
collected at 2, 4, 6, 8, 10, and 15 minutes, 
centrifuged, and the plasma frozen at -20
o
C prior to 
assay. 
Drug and Metabolite Analysis 
The procedure used for the assay of APAP and its 2 
major metabolites was similar to that described 
previously (9). Briefly, a reversed-phase HPLC assay 
was used for the detection of APAP and its 
metabolites. The mobile phase was 7% acetonitrile 
50 mM sodium sulfate and 50 mM potasssium 
phosphate buffer with a flow rate of 1.3 mL/min. 
APAP, AG, and AS were detected at 254 nm. 
Retention times were approximately 4.5, 6, 8, and 12 
minutes, respectively, for AG, AS, and APAP and the 
internal standard (3-acetamidophenol). For HPLC 
assay of ICG, the procedure used was similar to that 
described previously (10,11). Briefly, 
chromatography was performed on a reversed-phase 
column (Bondapack C18; Water's Associates, 
Milford, MA) employing a mobile phase of 50 mM 
phosphate buffer (50 mM KH2PO4:K2HPO4; pH = 
5.52):acetonitrile (55:45), with a flow of 2 mL/min. 
ICG was detected at 720 nm and had a retention time 
of approximately 5.5 minutes.  
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Free fraction of APAP and its metabolites AG and 
AS were determined by ultrafiltration (Amicon, 
Bedford, MA). Plasma from CF mice was spiked 
with APAP, AG, or AS and transferred to the sample 
reservoir of the filtration device and centrifuged at 
900 g for 10 minutes at ambient temperature. Total 
and free concentrations of APAP, AG, and AS were 
determined by HPLC. 
Pharmacokinetic and Statistical Analysis 
Pharmacokinetic analysis was performed using 
noncompartmental analysis with WinNonlin 
(Pharsight, Mountain View, CA). Assuming F = 1 for 
ip APAP, clearance (CL/F) of APAP, renal clearance 
(CLR), and formation clearance (CLf) of 
acetaminophen glucuronide (AG) and acetaminophen 
sulfate (AS) were determined. Formation clearances 
of AS and AG were calculated based on assumptions 
similar to those employed by the human study; that 
is, no sequential or renal metabolism occurred, and 
all metabolite formed was recovered in the urine. 
Because the disposition profile of ICG was best 
described by a 1-compartment model, 
pharmacokinetic parameters (CL, Cmax, k, and V) 
were determined by this approach. Pharmacokinetic 
data are expressed as mean ± SD. Comparison 
between values was made using a general linear 
models (glm) followed by least square means 
analysis. Data were analyzed using Statistical 
Analysis System (SAS Institute, Cary, NC). The 
acceptable level of statistical significance was P
.05.
RESULTS
APAP Pharmacokinetics in the CF Mouse 
Pharmacokinetic parameters of APAP (50 mg/kg, ip) 
determined in male and female CF mice are shown in 
Tables 1 and 2. A representative plasma profile of 
APAP and its metabolites AG and AS in a male CF 
mouse is represented in Fig. 1. Similar to CF patients, 
significant differences in renal clearance (CLR,AS) and 
clearance of formation (CLf,AS) of AS were noted 
between heterozygous and homozygous CF male 
mice. However, no significant differences in either 
total systemic clearance (CL/F, assuming F = 1), 
renal clearance (CLR,AG), or formation clearance 
(CLf,AG) were noted between the homozygous and 
heterozygous CF mice (Tables 1 and 2). 
Homozygous male mice did show a trend towards 
increased renal clearance (CLR,AG) and an increased 
clearance of formation (CLf,AG) of AG compared to 
the heterozygous males (controls) (Table 1), although 
statistical significance was not obtained in this case. 
Although a trend toward increased clearance was 
seen in homozygous females, these females did not 
differ significantly from the heterozygous females in 
either CLR or CLf for AG and AS (Table 2). 
Significant differences were noted between male and 
female CF mice in total clearance (CL/F) and renal 
clearance of AS (CLR,AS) (Tables 1 and 2), which was 
not unexpected in an inbred strain of mice. Sex-
selective expression of different enzymes has already 
been reported in mice (12,13). Sex differences in 
APAP sulfation and glucuronidation have been 
reported in Sprague Dawley rat hepatocytes where 
increased sulfation of APAP is reported in male rats 
(14). Such sex-specific differences have been 
reported for other substrates besides APAP like 
HMBA (7-hydroxymethyl-12-methyl-benz[a] 
anthracene). Adult female rat livers showed a much 
higher cytosolic sulfotransferase activity for HMBA 
metabolism compared to male rats (15). Sex 
differences have also been reported in glucuronide 
metabolism of pirmenol (an anti-arrhythmic drug 
developed by Warner Lambert/Parke Davis) (16). 
Other enzymes besides Phase II metabolic enzymes 
also show such sex-specific differences (12,17). 
Differences in transporter expression have also been 
recently reported (18,19). Although not much 
information regarding sex-specific expression of 
phenolsulfotransferase (PST), UDP-glucuronyl 
transferases (UGT), or transporter expression in 
humans or the cftr
m1UNC
-knockout mice is currently 
available in literature, it is likely that the sex-specific 
differences noted for APAP are attributable to 
differences in expression of specific enzymes 
involved in metabolism or transport of APAP 
metabolites. Urinary recovery of APAP was similar 
to that reported in humans where about 65% to 75% 
of APAP is excreted as the metabolites AG and AS, 
(Tables 1 and 2) (5). Free fraction (fu) of APAP and 
its metabolites AG and AS in plasma were not 
measurably different in the small number of samples 
analyzed (Tables 1 and 2). 
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Table 1. Pharmacokinetic Parameters for APAP and Its 
Conjugated Metabolites in Male CF Mice After 50 mg/kg 
Intraperatoneal Administration* 
Parameter CF Male Mice (-/-)CF Male Mice (+/-) 
CL/F(ml/min/kg) 34.8 ± 2.9
a c
 35.4 ± 4.8
c
fe, AG (%) 28.5 ± 6.4
c
 25.0 ± 6.4
c
CLR,AG (ml/min/kg) 6.3 ± 1.3 4.8 ± 3.0 
CLf,AG (ml/min/kg) 9.6 ± 2.1 8.9 ± 2.8 
fe, AS (%) 19.1 ± 3.3 12.3 ± 6. 
CLR,AS (ml/min/kg) 19.5 ± 3.8
b c
 12.9 ± 7.6 
CLf,AS (ml/min/kg) 10.4 ± 1.8
b
 6.7 ± 3.4 
fu,APAP 0.86 0.83 
fu,AG 0.87 0.82 
fu,AS 0.68 0.70 
*CL/F indicates relative plasma clearance of APAP; fe,AG, 
fraction of dose recovered in the urine as AG (units are 
expressed as APAP equivalents); CLR,AG, renal clearance of 
AG; CLf,AG, formation clearance of APAP to AG; fe,AS, fraction 
of dose recovered in the urine as AS (units are expressed as 
APAP equivalents); CLR,AS, renal clearance of AS; CLf, AS, 
formation clearance of APAP to AS; fu, APAP, free fraction of 
APAP; fu,AG, free fraction of AG; fu,AS, free fraction of AS.  
aMean ± SD, n = 6.  
bSignificant difference between homozygous and heterozygous 
CF males.  
cSignificant difference between CF males and CF females.
Table 2. Pharmacokinetics of APAP and its Conjugated 
Metabolites in Female CF Mice After 50 mg/kg 
Intraperitoneal Administration 
Parameter CF Female Mice (-/-)CF Female Mice (+/-) 
CL/F (ml/min/kg) 25.8 ± 2.8
b
  24.8 ± 3.0
b
fe, AG (mg/kg)  38.1 ± 7.7b  33.5 ± 7.9b
CLR,AG (ml/min/kg)  4.7 ± 0.8   4.1 ± 2.5  
CLf,AG (ml/min/kg)  9.4 ± 1.5   8.2 ± 1.6  
fe, AS (mg/kg) 35.7 ± 4.7 30.9 ± 7.2 
CLR,AS (ml/min/kg)  8.4 ± 1.4
b
  7.9 ± 2.0 
CLf,AS (ml/min/kg)  8.9 ± 1.4  7.5 ± 1.0  
fu,APAP 0.84  0.87  
fu,AG   0.85 0.85  
fu,AS  0.67  0.65 
aMean ± SD, n = 6. 
bSignificant difference between CF males and CF females. 
See Table 1 for parameter definitions.
Figure 1. Representative plasma concentration time 
profile of acetaminophen (APAP) (filled diamond) and 
its glucuronide (open square) and sulfate (open 
triangle) metabolites in a cystic fibrosis (-/-) male 
mouse administered APAP (50 mg/kg, ip).  
ICG Pharmacokinetics in the CF Mouse 
Following administration of 10 mg/kg ICG, 
pharmacokinetic parameters were determined (Table 
3) with a representative plasma profile (Fig. 2). The 
disposition profile for ICG was best described by a 1-
compartment model. This is similar to the human 
situation in which a 1-compartmental fit for ICG has 
been reported in CF patients (3,4). CF-knockout mice 
did not show any difference in total systemic 
clearance (CL), unlike the situation in CF patients, 
wherein increased clearance was reported to correlate 
with the severity of CF (2). Similar to the results with 
APAP, gender differences in clearance of ICG were 
noted in CF mice. Homozygous female CF-mice 
showed an increased V when compared with the 
heterozygous mice used as controls (Table 3). These 
results are in agreement with previous reports of an 
increase in V for ICG in CF patients (3,4). Similar to 
CF patients, homozygous CF-mice also showed a 
trend towards lower peak concentrations of ICG 
relative to heterozygous mice (Table 3). Blood-to-
plasma ratios for ICG were 0.58 ± 0.18 in (-/-) female 
mice vs. 0.55 ± 0.025 in (+/-) female mice. 
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Table 3. Pharmacokinetic Parameters for ICG in Male and Female CF Mice After a 10-mg/kg Intravenous Bolus* 
Parameter  Male (-/-)  Male (+/-) Female (-/-) Female (+/-) 
CL/F (ml/min/kg) 23.0 ± 6.0 25.0 ± 7.0  28.0 ± 7.1 30.0 ± 8.5 
Cmax (μ g/ml) 218 ± 71c 223 ± 51c 112 ± 38c 140 ± 14c
k (min
-1
) 1.5 ± 0.4c 1.4 ± 0.4  2.5 ± 1.0c 1.8 ± 0.4 
V (ml/kg) 49.0 ± 14c 47.0 ± 12c   96.0 ± 2.6b c 72.0 ± 6.9c
*CL indicates total plasma clearance of indocyanine green; V, apparent volume of distribution; 
K, elimination rate constant. 
aMean ± SD; n = 6. 
bSignificant difference between homozygous and heterozygous CF-females. 
cSignificant difference between CF males and CF females. 
Figure 2. Representative plasma concentration time 
profiles of indocyanine green (ICG) in cystic fibrosis +/- 
(open triangle) and -/- (filled diamond) male mice 
injected with ICG (10 mg/kg, iv) via the tail vein. 
DISCUSSION 
Studies in CF patients have revealed altered 
pharmacokinetics for diverse drugs such as 
gentamicin, tobramycin, dicloxacillin, cloxacillin, 
theophylline, cyclosporin, APAP, lorazepam, and 
ICG (3). Alterations in pharmacokinetics include 
lower plasma concentrations, increased total plasma 
clearance, and an increase in apparent steady-state 
volume of distribution. Mechanisms that account for 
and adequately describe these alterations in CF have 
not been determined. 
Elucidating a mechanism for altered absorption and 
clearance of drugs is unlikely if experimentation is 
limited to CF patients. A predictive animal model to 
study altered drug disposition in CF is therefore 
desirable. The objective of this study was to evaluate 
the cftr
m1UNC
 mouse (7) as a potential animal model to 
predict alterations in pharmacokinetics observed in 
CF patients, so that compounds that have altered 
disposition may be identified, and thus drug therapy 
may be optimized more rationally. This mouse model 
has altered gastrointestinal and hepatobiliary 
abnormalities similar to that seen in CF patients (20) 
but has not previously been evaluated as a model for 
drug disposition in CF.  
Preliminary studies were conducted using 2 model 
compounds, APAP and ICG, in CF-knockout mice 
using heterozygous (+/-) littermates as controls. 
Increased clearance of both APAP and ICG has been 
reported in CF patients (2,5). Increased clearance of 
APAP in CF patients has been attributed to greater 
metabolic clearance of APAP to AG and AS (5). 
CL/F was found to be 1.5-fold different between CF 
patients and controls (0.36 vs. 0.25 L/min per kg, 
respectively) with a 1.7-fold higher CLf of the 
glucuronide and sulfate. A trend toward a correlation 
between the NIH score (index of severity of the 
disease) and CLf, AG and CLf, AS was also found in CF 
patients (5).  
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These preliminary experiments with APAP in CF 
mice revealed results similar to those seen in humans; 
ie, a trend of increased CLf,AG and CLf,AS, although 
for the sample size employed, only CLf,AS was 
significantly different (Tables 1 and 2). Conversion 
of APAP to its major metabolites via the liver 
involves 3 distinct steps, uptake, metabolism, and 
efflux, and alterations in any of these could be 
responsible for the observed increased clearance.  
APAP is a moderately water- and lipid-soluble weak 
organic acid with a pKa of 9.5, and is largely 
uncharged at physiological pH. It is reasonable to 
assume that APAP should be able to cross the cell 
membrane by simple diffusion alone. However, the 
presence of a carrier-mediated system that may 
contribute to uptake at concentrations encountered in 
vivo has been reported (21). Two metabolic 
inhibitors, 2,4-dinitrophenol and iodoacetate, reduced 
the uptake of APAP into hepatocytes, suggesting that 
uptake of acetaminophen is a combination of a 
saturable active process and simple diffusion (22).  
Conjugation of the drug within the cell is the second 
step. Because the glucuronidation of APAP at the 
dose used in the study is unlikely to be rate-limited 
by the availability of the cofactor UDP glucuronic 
acid (23,24), increased glucuronidation of APAP in 
the CF-knockout mice may be attributable to an 
induction or activation of UGT. Preliminary in vitro 
studies of APAP glucuronidation using mouse liver 
microsomes suggest no apparent difference in either 
Vm or Km for metabolism of APAP by UGT. 
Increased formation of AS could either arise from an 
increased hepatic PST activity or from an increase in 
inorganic sulfate concentration, a precursor to 3-
phospho adenosine 5’-phosphosulfate (PAPS), and 
these options are currently being investigated. 
However, no differences in inorganic sulfate levels 
were noted in CF patients, despite a higher CLf,AS
(14); therefore, increased inorganic sulfate levels are 
unlikely to be the cause of higher CLf,AS in the mice.  
Transport of the conjugates out of the cell may also 
be rate-limiting, which would result in an increase in 
levels of intracellular conjugate and possibly result in 
product inhibition (25-27). Analogous to rats and 
humans, CF mice probably excrete AG from 
hepatocytes via either oatp (organic anion 
transporting polypeptide), or mrp1 (multidrug 
resistance associated protein-1) or some as yet 
unidentified transporter involved in the transport of 
anions. As with AG, AS is very polar and is a strong 
acid; therefore, it may also depend on membrane 
transporters to be excreted from hepatocytes. 
Previous studies in fetal sheep indicate that AG and 
AS are not passively transported across the placenta 
(28); therefore, it is likely that their removal from 
hepatocytes is facilitated. 
Increased clearance of drugs like APAP in CF could 
arise from an increased expression of transporters, 
resulting in either increased uptake or efflux of the 
drug. There is precedence for this statement in that 
coordinate regulation between expression of cftr and 
mdr1 has been reported to occur across several 
species (29-31). A recent study by Trezise et al, 1997 
(29) suggests that expression of transporters like 
mdr1 (multidrug resistance) may be coordinately 
regulated with ctfr expression. An inverse 
relationship between cftr and mdr1 expression in the 
CF mouse with heterozygous mice showing an 
intermediate level of expression and homozygous CF 
competent mice (+/+) having lowest levels of mdr 
has been demonstrated.  
ICG is a high extraction ratio probe in humans, which 
is exclusively cleared by the liver. ICG is efficiently 
excreted in bile without the need for metabolism, 
because of its large molecular weight and inherent 
charge. However, it appears that in the CF-knockout 
mice, ICG is only a moderate extraction ratio drug (E 
= 0.6). This conclusion is based on a published value 
for hepatic blood flow in the mouse of 86 mL/min 
per kg (32). Because both hepatic blood flow and bile 
acid uptake have been found to be normal in patients 
with CF (33), ICG should provide a more direct 
measure of whether specific hepatic transporters are 
altered in CF. It is possible that the genetic defect in 
CF that alters transmembrane regulation of ion flux 
(ie, cystic fibrosis transmembrane regulator [cftr] 
protein) may also increase either the cellular uptake 
of ICG or its eventual secretion into the bile. 
Following administration of ICG, homozygous CF-
knockout mice had results qualitatively similar to CF 
patients, with a trend toward a decreased Cmax and an 
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increased V relative to heterozygous mice. However, 
in contrast to humans, no difference in CL of ICG 
was observed in the cftr mice relative to 
heterozygous controls (Table 3). It is probable that 
the rate-limiting step in the elimination of ICG, either 
uptake or efflux, may be different between species.  
Increased volume of distribution has been reported 
for a large number of compounds in CF (eg, 
antipyrine, lorazepam, and ICG) (2). It has been 
suggested that in CF patients, chronic reduction in 
systemic arterial oxygen saturation, which is 
observed with increasing severity of pulmonary 
disease, is often associated with increases in both 
erythrocyte count and plasma volume. These 
alterations result in an increase in body water/body 
mass ratio, effectively increasing the available 
distribution space for drugs that partition to both 
intravascular and extravascular spaces (2). It should 
be noted that this difference in V in female CF mice 
is not attributable to altered blood-to-plasma ratio of 
ICG. Blood-to-plasma ratios for ICG were not 
different between homozygous and heterozygous 
female mice.  
In summary, this study shows that, similar to CF 
patients, CLf and CLR of AS is increased in 
homozygous CF male mice relative to heterozygous 
(+/-) controls. A trend toward an increased CLf and
CLR of AG was noted, with no significant 
differences. This trend may be attributed to the fact 
that a diverse group of mice (ages 20 to 48 weeks) 
were used in this study because of limited availability 
of these mice. Also, (+/+) mice were not used as 
controls in these studies. The studies by Trezise et al 
in 1997 (29) indicate that if the increased clearance 
comes from expression levels of a transporter, then 
(+/+) mice would serve as better controls. Results 
with ICG indicate that homozygous CF mice 
demonstrate a trend toward a decreased Cmax and an 
increased V relative to heterozygous mice. However, 
in contrast to results from CF patients, no difference 
in CL of ICG is noted in CF mice. The use of (+/+) 
mice as controls in future studies may increase the 
ability to discriminate the effects of altered cftr on 
drug disposition.  
We conclude that the CF-knockout mouse model has 
potential for being employed as an animal model for 
predicting altered clearance in CF patients. Future 
studies using (+/+) mice as controls and a wider 
range of drugs are ongoing.  
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